Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RACE - Rapid Amplification of cDNA Ends02:35

RACE - Rapid Amplification of cDNA Ends

5.9K
Rapid Amplification of cDNA Ends, or RACE, is one of the most effective methods to obtain a full-length cDNA from an mRNA sequence between a known internal region to the unknown sequence at the 5’ or 3’ end. The unknown region is cloned in the cDNA by a gene-specific primer that binds the known end, and a hybrid primer that attaches a predefined anchor sequence to the unknown end of the cDNA. The sequence in between is amplified by PCR with an anchor primer and a gene-specific...
5.9K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

12.3K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.3K
Midrange01:07

Midrange

2.8K
A somewhat easy to compute quantitative estimate of a data set’s central tendency is its midrange, which is defined as the mean of the minimum and maximum values of an ordered data set.
Simply put, the midrange is half of the data set’s range. Similar to the mean, the midrange is sensitive to the extreme values and hence the prospective outliers. However, unlike the mean, the midrange is not sensitive to all the values of the data set that lie in the middle. Thus, it is prone to...
2.8K
Three Developmental Domains01:29

Three Developmental Domains

1.5K
Human development is typically examined across three main domains: physical, cognitive, and socio-emotional. These domains represent the significant areas of change and continuity throughout the lifespan, from infancy to late adulthood.
Physical Development
Physical processes, also known as maturation, encompass the biological changes that occur across an individual's life. These changes begin with genetic inheritance and continue through various stages, including growth in height and weight,...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alternative use of bisphosphonate therapy for rheumatic disease.

Current pharmaceutical design·2010
Same author

Validity of the polymyalgia rheumatica activity score in primary care practice.

Annals of the rheumatic diseases·2008
Same author

Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.

Annals of the rheumatic diseases·2005
Same author

[Chronic lower back pain: a new therapeutic approach].

Neuro-Chirurgie·2004
Same author

Poor predictive value of antinucleosome and antineutrophil cytoplasmic antibodies in a 270 inception cohort of patients with early naked arthritis of less than one year's duration.

Annals of the rheumatic diseases·2002
Same author

Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis.

Rheumatology (Oxford, England)·2002
Same journal

The expanded cardiovascular risk prediction score as a cardiovascular mortality predictor in rheumatoid arthritis.

Clinical and experimental rheumatology·2026
Same journal

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same journal

Clinical features and gastrointestinal bleeding risk factors in IgA vasculitis patients: a retrospective study in a large volume centre.

Clinical and experimental rheumatology·2026
Same journal

Reply to the comment on: The microbiota in axial spondyloarthritis: what have we learned from Mendelian randomisation studies?

Clinical and experimental rheumatology·2026
Same journal

Comprehensive evaluation of bone structural and microarchitectural changes in rheumatoid arthritis treated with baricitinib using HR-pQCT, imaging, and biomarker analyses.

Clinical and experimental rheumatology·2026
Same journal

Tracking interstitial lung disease in systemic sclerosis: integrating lung magnetic resonance imaging into a clinically oriented multimodal follow-up strategy.

Clinical and experimental rheumatology·2026
See all related articles

Related Experiment Video

Updated: Apr 21, 2026

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

10.0K

RAPID3? Aptly named!

J-M Berthelot1

  • 1Rheumatology Unit, Nantes University Hospital, Hôtel-Dieu, 44093 Nantes Cedex, France. jeanmarie.berthelot@chu-nantes.fr.

Clinical and Experimental Rheumatology
|November 4, 2014
PubMed
Summary
This summary is machine-generated.

The RAPID3 score, a patient self-report tool, efficiently assesses disease activity in rheumatologic conditions. It offers a quick and comparable alternative to traditional measures for remission and disease progression, aiding in clinical trial and patient monitoring.

More Related Videos

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer
09:38

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer

Published on: March 28, 2018

11.9K
3' End Sequencing Library Preparation with A-seq2
12:01

3' End Sequencing Library Preparation with A-seq2

Published on: October 10, 2017

13.5K

Related Experiment Videos

Last Updated: Apr 21, 2026

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells
12:13

Zinc-finger Nuclease Enhanced Gene Targeting in Human Embryonic Stem Cells

Published on: August 23, 2014

10.0K
Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer
09:38

Adapting 3' Rapid Amplification of CDNA Ends to Map Transcripts in Cancer

Published on: March 28, 2018

11.9K
3' End Sequencing Library Preparation with A-seq2
12:01

3' End Sequencing Library Preparation with A-seq2

Published on: October 10, 2017

13.5K

Area of Science:

  • Rheumatology
  • Patient-Reported Outcomes
  • Clinical Assessment

Background:

  • The Rheumatology Assessment of Pain, Impairment, and Distress 3 (RAPID3) score is a composite patient self-report measure.
  • It sums three 0-10 scales: pain, functional impairment (MDHAQ), and patient global estimate, taking only 5 seconds to complete.
  • While applicable to all rheumatic diseases, its utility is primarily explored in rheumatoid arthritis.

Purpose of the Study:

  • To evaluate the RAPID3 score's efficacy and applications in rheumatologic conditions.
  • To compare RAPID3-based remission criteria with established measures.
  • To explore RAPID3's role in clinical trials, disease progression prediction, and remote patient monitoring.

Main Methods:

  • The RAPID3 score was analyzed for its speed, applicability across rheumatologic conditions, and correlation with disease activity.
  • Remission criteria using RAPID3 (≤ 3/30 with ≤ 1 swollen joint) were compared to Boolean, SDAI, CDAI, and DAS28 criteria.
  • RAPID3's performance in distinguishing active drugs from placebos in clinical trials was assessed.
  • Its ability to predict structural disease progression and facilitate remote monitoring (e.g., flare detection) was examined.

Main Results:

  • RAPID3 requires minimal time (5 seconds) and is broadly applicable, with established cutoffs for low (<6/30) and high (>12/30) disease activity in rheumatoid arthritis.
  • RAPID3-based remission criteria (≤ 3/30 + ≤ 1 swollen joint) demonstrate comparability to established remission criteria.
  • RAPID3 exhibits performance similar to DAS28 in clinical trials for differentiating drug efficacy and predicts future structural damage.
  • Remote monitoring using RAPID3 allows for calculating disease activity over time and detecting flares.

Conclusions:

  • RAPID3 is a rapid, valid patient-reported outcome measure for assessing disease activity and remission in rheumatologic conditions.
  • It serves as a valuable tool in clinical trials and can enhance patient monitoring between visits, complementing traditional assessments.
  • While not a replacement for comprehensive clinical evaluation (including joint counts and physician assessment), combining RAPID3 with DAS28 may offer faster or more sensitive confirmation of treatment efficacy.
  • Improved patient engagement through measures like RAPID3 can strengthen the patient-physician relationship and treatment adherence.